Biodesix (BDSX) Q2 FY26 earnings call

Biodesix delivered another quarter of robust top-line growth, driven by strong diagnostic testing volumes and improved average revenue per test. The company demonstrated significant operational leverage, maintaining high gross margins and improving adjusted EBITDA, as it continues its disciplined path towards sustained profitability. Commercial expansion, particularly in primary care, and compelling clinical evidence are key drivers of adoption.